



## MEETING LOG

**SUBJECT:** UL 8400 Biocompatibility Task Group Meeting on Virtual Reality (VR), Augmented Reality (AR), and Mixed Reality (MR) Technology Equipment

**OP PLAN ENTRY:** Wearable Technology

**DATE OF MEETING:** 4/23/2025

**LOCATION OF MEETING:** Virtual

**CPSC STAFF FILING MEETING LOG:** Stephen Harsanyi (ESHF)

**FILING DATE:** 4/24/2025

**CPSC ATTENDEE(S):** Brad Gordon (ESMC), John Gordon (HSTR), Stephen Harsanyi (ESHF), and Suad Wanna-Nakamura (HSPP)

**NON-CPSC ATTENDEE(S):** Contact ULSE for the full attendee list.

### Summary of Meeting:

The Biocompatibility Task Group for ULSE Technical Committee (TC) 8400 on Virtual Reality (VR), Augmented Reality (AR), and Mixed Reality (MR) Technology Equipment (“immersive technologies”), convened to improve the biocompatibility requirements specified in the standard. The task group predominantly discussed requirements pertaining to cleaning, disinfection, maintenance, and storage of immersive technologies. CPSC staff recommended the standard accounts for reasonably foreseeable use, including cleaning agents that may not be specified in the instructional literature, or which may go against the instructional literature.

Additional topics discussed included inhalation risks and prolonged skin contact. One member opined that off-gassing from immersive technologies is not a concern for inhalation. CPSC staff responded that material off-gassing of volatile organic compounds has been a known concern for wearable products, and that the subject immersive technologies can be in direct contact with the face for extended periods. The group discussed whether the existing requirements for skin compatibility adequately protect consumers against potential harmful exposure from limited use, given the standard specifically refers to “prolonged skin contact,” which is defined in the standard as follows: “10 or more minutes on 3 or more occasions over 2 weeks, or 30 minutes on one or more occasions within 2 weeks.” One member opined that a harmful reaction to such a limited period of exposure would be indicative of pre-sensitization that manufacturers cannot address. CPSC staff challenged this assertion and requested further discussion in the next meeting.

### Next Steps:

The Biocompatibility Task Group plans to reconvene on May 21, 2025, at 1 PM, ET, to continue developing the skin and inhalation compatibility requirements.